Nicholas Piramal no 2 Indian pharma firm

19 January 2001

Nicholas Piramal of India says it has become the second biggestpharmaceutical company in India, after GlaxoSmithKline, through the acquisition of a 40% stake in Rhone-Poulenc India. NP recently purchased some 1.8 million shares from R-PI's majority shareholder, Aventis Pharma, at 875 rupees ($18.72) each (Marketletter January 1 & 8).

NP to take further 20% stake in R-PI

The deal gives NP over a 5% share of the Indian pharmaceutical market, and this latest acquisition is the company's 12th since it announced its strategy to expand through mergers and alliances. NP will make an open offer to acquire an additional 20% stake in RP-I, also at 875 rupees per share. Currently, the public holds a 33% stake in R-PI, and financial institutions own the rest.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight